SequelSEC

Travere Therapeutics, Inc. TVTX

Pharmaceutical Preparations · CIK 0001438533 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$169.58M
Fiscal year ended 2026-06-30
Operating income
$3.95M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Travere Therapeutics, Inc. (TVTX) reported revenue of $169.58M and net income of -$34.80M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Travere Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Travere Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$169.58M$127.20M$129.69M$164.86M$114.45M$81.73M$74.79M$62.90M$54.12M$41.37M
Cost of revenue$2.17M$1.95M$2.55M$1.58M$1.52M$4.68M$2.55M$1.63M$2.06M$1.50M
Gross profit$167.41M$125.25M$127.14M$163.27M$112.93M$77.05M$72.23M$61.27M$52.06M$39.87M
Operating income$3.95M-$36.92M-$32.43M$24.93M-$12.65M-$42.67M-$60.74M-$56.15M-$67.70M-$139.24M
Net income-$34.80M-$37.10M$2.73M$25.71M-$12.76M-$41.23M-$60.26M-$54.81M-$70.41M-$136.06M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 93.48Mshares 91.87MUnavailableshares 102.62Mshares 88.95Mshares 88.36MUnavailableshares 77.78Mshares 77.50Mshares 77.14M
Pretax income-$35.00M-$36.72M-$21.06M$25.71M-$12.74M-$41.19M-$60.34M-$54.84M-$69.57M-$135.77M
Income tax expense-$204.00K-$120.00K$921.00K$8.00K$20.00K$39.00K-$72.00K-$84.00K$85.00K$191.00K
Diluted EPS$-0.37$-0.40$0.03$0.28$-0.14$-0.47$-0.71$-0.70$-0.91$-1.76
Selling, general & administrative$96.11M$80.25M$101.69M$86.45M$62.58M$60.41M$69.50M$65.62M$64.78M$64.22M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Travere Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$117.74M$78.36M$93.04M$110.93M$75.15M$61.90M$58.54M$36.41M$32.29M$43.25M
Total assets$799.36M$555.19M$605.19M$538.58M$555.31M$548.80M$594.12M$504.41M$551.12M$663.55M
Current assets$615.14M$392.68M$437.56M$371.11M$379.57M$374.17M$416.70M$324.74M$368.98M$481.08M
Total liabilities$774.84M$456.46M$490.36M$465.02M$522.56M$515.98M$535.05M$534.86M$535.97M$589.48M
Current liabilities$152.02M$125.44M$159.90M$135.07M$189.54M$182.46M$200.75M$190.04M$121.27M$173.23M
Total equity incl. NCI$24.52M$98.73M$114.83M$73.56M$32.75M$32.82M$59.08M-$30.45M$15.15M$74.07M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$40.05M$37.05M$36.16M$37.55M$37.68M$38.00M$41.86M$42.88M$42.98M$42.31M
Accounts receivable$80.64M$87.30M$80.13M$82.98M$38.72M$34.38M$27.12M$25.17M$24.47M$22.73M
GoodwillUnavailableUnavailableUnavailable$800.00K$800.00K$800.00K$800.00K$800.00K$800.00K$800.00K
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$7.50M$12.91M$24.80M$18.22M$19.13M$15.37M$23.53M$23.20M$25.84M$16.72M

Cash flow

Travere Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow$58.07M-$40.37M$60.68M$14.32M$4.98M-$42.19M-$35.72M-$42.51M-$40.24M-$119.00M
Capital expendituresUnavailableUnavailableUnavailable$140.00KUnavailableUnavailableUnavailable$0$82.00K$0
Investing cash flow-$206.29M$21.55M-$104.84M$86.59M$4.85M$41.29M-$80.31M$46.13M$28.61M$104.90M
Financing cash flow$187.52M$4.20M$26.68M-$65.34M$1.48M$3.72M$139.12M$46.00K$782.00K-$525.00K
Net change in cash$39.37M-$14.67M-$17.90M$35.78M$13.26M$3.36M$22.13M$4.12M-$10.96M-$14.92M
Stock-based compensation$21.79M$16.15M$11.46M$11.26M$10.65M$11.49M$9.21M$8.02M$9.92M$9.76M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$4.23M$25.21M$18.14M$15.79M$14.02M$12.80M$12.09M$11.24M$10.34M$9.88M

Derived

Travere Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailable$14.18MUnavailableUnavailableUnavailable-$42.51M-$40.32MUnavailable
Gross margin98.7%98.5%98.0%99.0%98.7%94.3%96.6%97.4%96.2%96.4%
Operating margin2.3%-29.0%-25.0%15.1%-11.1%-52.2%-81.2%-89.3%-125.1%-336.5%
FCF marginUnavailableUnavailableUnavailable8.6%UnavailableUnavailableUnavailable-67.6%-74.5%Unavailable
SBC / revenue12.8%12.7%8.8%6.8%9.3%14.1%12.3%12.8%18.3%23.6%
Current ratio4.05x3.13x2.74x2.75x2.00x2.05x2.08x1.71x3.04x2.78x
Revenue YoY growth48.2%55.6%73.4%162.1%111.5%97.5%66.0%69.6%68.1%33.9%
Net margin-20.5%-29.2%2.1%15.6%-11.1%-50.4%-80.6%-87.1%-130.1%-328.9%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable0.1%UnavailableUnavailableUnavailable0.0%0.2%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TVTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2022-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.